

AWARD NUMBER: W81XWH-19-1-0219

TITLE: Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women

PRINCIPAL INVESTIGATOR: Amy DiVasta, MD, MMSc

CONTRACTING ORGANIZATION: Boston Children's Hospital

REPORT DATE: OCTOBER 2023

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution is unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE*Form Approved*
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE OCTOBER 2023	2. REPORT TYPE Annual	3. DATES COVERED 1SEPT2022 - 31AUG2023
4. TITLE AND SUBTITLE Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women		5a. CONTRACT NUMBER W81XWH-19-1-0219
		5b. GRANT NUMBER
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Amy D. DiVasta, MD, MMSc E-Mail: amy.divasta@childrens.harvard.edu		5d. PROJECT NUMBER
		5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Boston Children's Hospital 300 Longwood Avenue Boston, MA 02115		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		
13. SUPPLEMENTARY NOTES		

14. ABSTRACT

Background: Endometriosis afflicts millions of women worldwide, resulting in the loss of academic, athletic, social, and professional success. Women can experience chronic pain, fertility challenges, and higher risk of cardiovascular disease. As no cure exists, patients require disease management across the lifespan. However, current therapies are suboptimal, and pain is often left untreated. Medications with favorable long-term safety, efficacy, and tolerability are desperately needed. As endometriosis is dependent on angiogenesis for its growth and maintenance, we believe that angiogenesis inhibitors are a promising option for treatment. However, these medications have not yet been studied since the currently approved angiogenesis inhibitors induce severe side effects and are teratogenic, making them inappropriate for use in reproductive-age women. We will overcome this obstacle by repurposing an existing drug (cabergoline) that has an acceptable safety profile as an angiogenesis inhibitor to treat chronic pelvic pain associated with endometriosis.

Hypothesis/Objectives: We propose to conduct a randomized, double-blind, placebo controlled trial to determine the efficacy of cabergoline as an adjunct treatment for persistent pain due to endometriosis.

Specific Aims: (1) To determine the extent to which cabergoline adjunct treatment alleviates persistent pelvic pain suffered by women with laparoscopically-proven endometriosis. We hypothesize that after 6 months, subjects randomized to cabergoline (n=40) will demonstrate decreased pain measures, improved functional disability scores, and increased quality of life scores compared to baseline and to subjects randomized to placebo (n=40). (2) To measure the impact of cabergoline on inflammation, angiogenesis, and cardiovascular risk in endometriosis. We hypothesize that cabergoline will significantly decrease angiogenic and inflammatory biomarkers over 6 months, while placebo therapy will have no effect on these same markers. We also hypothesize that clinical markers of cardiovascular risk will improve over 6 months in subjects receiving cabergoline. (3) To determine if the magnitude of central hypersensitization in women with endometriosis differs from healthy, age-matched controls, and whether 6 months of cabergoline therapy will alter these levels. We hypothesize that subjects with endometriosis will more frequently demonstrate central hypersensitization compared to healthy females, and that this increased frequency will decline with cabergoline therapy.

Study Design: The study is a randomized, double-blind, placebo controlled trial. Participants will be randomized to either cabergoline 0.5 mg by mouth twice weekly or placebo tablet by mouth twice weekly. Primary outcomes include validated measures of pain assessed in multiple dimensions, including physical pain, emotional symptoms, quality of life, sexual function, and ability to function in daily life. Secondary outcomes include angiogenic and inflammatory biomarkers, measures of vascular resistance, and a measurement of central hypersensitization to pain.

15. SUBJECT TERMS

Endometriosis; chronic pelvic pain; angiogenesis; cardiovascular risk; central hypersensitization

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRDC
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
U	U	U	UU	36	

Standard Form 298 (Rev.
8-98)

Prescribed by ANSI Std.
Z39.18

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	5
2. Keywords	5
3. Accomplishments	5-8
4. Impact	8
5. Changes/Problems	8-11
6. Products	11-12
7. Participants & Other Collaborating Organizations	12-16
8. Special Reporting Requirements	16
9. Appendix	16-36

1. INTRODUCTION:

Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double-blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial utilizes a novel, non-hormonal, non-surgical, therapeutic approach aimed at alleviating the pain and suffering associated with this common chronic disease that currently has limited treatment options.

2. KEYWORDS:

Endometriosis, Pelvic pain, Adjunct therapy, Angiogenesis, Cabergoline, Pulse Wave Velocity, Cardiovascular risk; Central hypersensitization

3. ACCOMPLISHMENTS:

What were the major goals of the project?

Major Task 1: Launch the randomized clinical trial

Major Task 2: Complete enrollment of n=80 study subjects

Major Task 3: Obtain data required to successfully complete Specific Aim 2

Major Task 4: Prospectively measure Quantitative Sensory Testing at baseline, 3 month, and 6 month study visits

Major Task 5: Complete study and analyze the data from the randomized controlled trial

What was accomplished under these goals?


Major Task 1: Launch the randomized clinical trial (completed)

The trial was successfully launched in Year 1.

Major Task 2: Complete enrollment of the n=80 subjects (in progress)

Subject recruitment, screening, and enrollment continued in Year 4. Since the pandemic, the modal shift in patient care to telemedicine has resulted in fewer potential in-person touchpoint for study staff and prospective participants, and we experienced delays in our recruitment goal. We continue to make efforts to improve and expand our recruitment methods.

Recruitment history to date is displayed in the graphic below:



Two Data and Safety Monitoring Board (DSMB) meetings occurred during Year 4, in October 2022 and May 2023. No concerns or recommendations regarding safety were raised at the sixth DSMB meeting in May 2023. In consultation with the DSMB, we removed the COVID-19 questionnaire in July 2023. The questionnaire was administered between February 2021 and July 2023 to capture data from our study participants about the pandemic, including symptoms, testing, and vaccination status.

The independent study monitor conducted two visits in Year 4, in November 2022 and May 2023. No significant concerns were identified by the study monitor. These reports were filed with the BCH IRB during the annual continuing review.

Major Task 3: Obtain data required to successfully complete Specific Aim 2 (in progress)

Study outcome measures have been collected at all in-person visits. Pulse Wave Velocity (PWV) measurements were collected at all baseline and 6 month visits with two exceptions. One baseline and one 6 month visits have incomplete PWV data with 2 out of 3 readings completed due to time constraints and difficulty with PWV reading of the femoral artery.

Collection of specimens for inflammatory and angiogenic biomarkers has occurred at each visit with the exception of six laboratory errors in the last year. Two errors occurred due to thawing and hemolysis of the samples, which resulted in missing TNF-a from a 6 month visit, and missing TNF-a, biomarkers, and saved serum aliquots from a 3 month visit. Two minor deviations occurred due to insufficient volume of the samples collected that resulted in missing one vial of saved serum from a 3-month visit, and three vials of saved serum from another 3-month visit. One processing error resulted in missing TNF-a from a 3-month visit, and one lab order error resulted in missing

ESR from a 3 month visit. We have been working closely with the Experimental Therapeutics Unit (ETU) to minimize the risk of laboratory errors including double-checks and having senior lab staff to check prior to processing our samples. Due to unresolved issues with errors in ESR analysis at our send out lab (Quest Diagnostics), we also pivoted into sending ESR samples to the Boston Children's Hospital (BCH) clinical lab to limit errors. We have had no further unreported samples since initiating this change in ESR analysis.

Major Task 4: Prospective measure Quantitative Sensory Testing at baseline, 3 month, and 6 month visits (in progress)

The Quantitative Sensory Testing has been collected at all in-person visits, with one exception. Due to an unexpected battery issue with the pressure algometer, one pressure sensation test is missing from a 3 month visit. Research assistants have been trained in the proper conduct of the Quantitative Sensory Testing protocol by Co-investigator Dr. Christine Sieberg's Pediatric Pain Lab. Study research assistants participated in a recent re-training assessment, given staff changes that occurred over the last year. While reviewing the NOTE Study QST, study staff discovered a minor drift with the language study staff used to describe the test to participants at study visits. The drift was immediately reported to the PI and team. In consultation with Dr. Christine Sieberg, we amended the script and QST manual to retain consistency with the QST administration and minimize further impact on the future study visits. Study staff created a QST video as a reference to be used in the future RA trainings and to avoid future drift.

Major Task 5: Complete study and analyze the data from the trial (in progress)

The data are being prospectively entered into our REDCap database. A systematic data double-checking protocol will continue periodically throughout the trial. In addition, the independent study monitor reviews every entered value for every fifth participant as part of study monitoring visits.

We are holding regular meetings with our biostatistician to continually review and clean the data. In the upcoming quarter, we will be conducting interim data analysis and the biostatistician will share the analysis with the DSMB at the next bi-annual meeting. Safety measures are analyzed in an unblinded fashion before all DSMB meetings. These analyses are conducted by the statistician and shared only with the unblinded DSMB members. No safety concerns were raised to the investigators after review.

What opportunities for training and professional development has the project provided?

The research assistants involved in the study received mentorship from Ms. Jenny Sadler Gallagher regarding the conduct of study visits, techniques for obtaining informed consent, and the maintenance of the REDCap database. Ms. Meg Bolan joined the team as Research Assistant to recruit participants from an additional site, Beth Israel Deaconess Medical Center (BIDMC). Ms. Esther Kim and Ms. Emma Draisin have taken on a mentorship role while training Ms. Bolan on all study protocols. The study team has also taken advantage of training and educational opportunities provided by Boston Children's Hospital, including training on Part 11 compliant databases. The research assistants, coordinator, and PI meet bi-weekly to discuss and review ongoing protocol and training as needed. In July 2023, the research assistants received an in-person QST training led by Dr. Sieberg as part of a new study personnel training for our sister protocol, NOTE Study Expansion.

Dr. DiVasta was appointed as the permanent Chief of the Division of Adolescent and Young Adult Medicine at Boston Children’s Hospital in November 2022 after her assumption of the Interim Chief position since September 2021.

How were the results disseminated to communities of interest?

Nothing to report at this time.

What do you plan to do during the next reporting period to accomplish the goals?

In the coming quarters, we will continue to focus on recruitment of new subjects to meet recruitment goals. We will also continue to hold bi-weekly team meetings to discuss recruitment status, challenges and create strategic recruitment solutions to address recruitment deficits, Recruitment updates will continue to be shared with to our referring providers and research assistants will continue to work closely with the providers to support efficient referral process.

In coordination with the Cardiology study team, we are pursuing training for our research assistants in PWV in an effort to facilitate easy scheduling of study visits and remove any barriers to making study more accessible to interested individuals.

As discussed above, we removed the COVID-19 questionnaire in consultation with the DSMB. Our previously developed COVID-19 contingency plan will be maintained in order to conduct any visits should rising of COVID-19 cases occur and impact our ability to hold in-person visits.

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

Nothing to report at this time.

What was the impact on other disciplines?

Nothing to report at this time.

What was the impact on technology transfer?

Nothing to report at this time.

What was the impact on society beyond science and technology?

Nothing to report at this time.

5. CHANGES/PROBLEMS:

In the last quarter of Year 4, we received approval from the U.S. Army Medical Research and Development Command for a 12-month no-cost extension of our project, with a new end date of August 31, 2024. Although we have made progress towards our study goals over the last year, our project was impacted with delays in the study timeline due to COVID-19 pandemic and the shut-down and slow re-opening of research activities at Boston Children’s Hospital during 2020 – 2022. With the 12-month extension to the study, we are hopeful that we will be able to meet the study aims as funded.

In Year 4, 5 amendments to the study protocol were submitted to and approved by our IRB. No significant changes to the primary study outcomes, interventions, risk/benefit ratio, study procedures, or sample size/patient population have occurred.

Amendment approved 11/4/2022

- Reformatted Daily Symptom Diary to make the layout more user-friendly and easier to fill out; no changes were made to the questions in the form, information collected or frequency of responses.
- Redesigned study brochure (tri-fold brochure) to make it easier to read and added a QR code for participants' convenience. No changes were made to the content, but format, font and color.
- Amended a sentence in DSMB charter about AE reporting period; updated it from 72 hours to 24-48 hours, which is consistent with the study protocol.

Amendment approved 1/24/2023

- Updated study document (protocol, informed consent form) to reflect study personnel change (addition of Margaret Bolan as Research Assistant).
- Updated protocol to grant Research Assistants access to medical records of patients being seen by referring physicians to identify patients who are potentially eligible for study participation before a scheduled clinic visit.

Amendment approved 3/10/2023

- Added recruitment material, a video overview of the study. The language used in the video is largely the same as language used in previously approved recruitment material, and the video was posted on previously approved platforms (such as Instagram and Facebook). Video and written script of the video were uploaded to Cherp for IRB review and approval.

Amendment approved 4/6/2023

- Updated paper protocol to reflect the addition of EMR review to our recruitment efforts, as approved and documented in the SmartForm protocol.
- Added a slightly varied version of the PI Outreach letter to specifically reach out to physicians already aware of NOTE.

Amendment approved 7/7/2023

- Updated the protocol to add BIDMC as a local external site to reflect that BIDMC will be involved in recruitment and identification of potentially eligible participants.
- Removed the COVID questionnaire from CRF 8.
- Updated the Survey packet under the 'Protocol and Appendices' section.
- Added BIDMC specific recruitment materials, which match our sister protocol NOTE Expansion (IRBP00040523).
- Removed a staff member (Sukanya Shukla) from the research team since she left BCH.

Amendment 7/24/2023

- Updated hard copy protocol to reflect the addition of BCH Lab Control as one of the processing sites for safety labs.

- Updated staff names on the list of individuals who will be given access to private health information to reflect the latest staff of research team who have access to private health information.
- Updated physician name mentioned in the Data and Safety Monitoring section of SmartForm to match the study DSMB charter.

As previously discussed, the expansion of the NOTE-2 Study via a separate funding mechanism (foundation/philanthropy) at external sites is currently underway. This expansion operates under a separate IRB protocol, which received its full approval from the Boston Children’s IRB on 06/28/2022. At the time of this report, recruitment at BIDMC is continuing and the first patient has enrolled. Thomas Jefferson University hired and completed training of a Research Assistant. Two additional sites are in contract negotiations. There is no funding overlap between the two protocols, although the scientific objectives are the same. With this expansion, we plan to increase the sample size by n=60 participants funded by the foundation/philanthropy (new total n=140 participants).

Changes in approach and reasons for change

We expanded and strategized our approach to recruitment to address the challenge with recruitment due to the transition in the format of clinical visits from in-person to telehealth visits post-pandemic, which resulted in fewer potential in-person touchpoints for the study team and prospective participants. Since the last annual report, our study staff have been prescreening medical records of patients of referring providers to facilitate an easier provider referral process. We also added a PI outreach letter to contact the providers of our previous and current participants who may already be aware of our study that could refer their potentially eligible patients. Our team has also been working closely with the Adolescent Gynecology Clinic and the BCH Center for Young Women’s Health (CYWH) to identify potential recruitment opportunities, including the Endometriosis Awareness Month in March. We collaborated with the CYWH to create and disseminate multimedia material about our study to help educate young women about endometriosis. We will continue to pursue multiple recruitment avenues, including: maintaining recruitment web, following up with any participants recruited in earlier quarters who expressed hesitancy in participation due to the COVID-19 pandemic or other personal reasons but may now be interested, and reaching out to endometriosis advocacy groups. We will also explore potential in-person recruitment option by participating in the divisional Research Table recruitment opportunity in the BCH Adolescent/Young Adult Medicine clinic. We have also consulted with other researchers within BCH Adolescent/Young Adult Medicine to discuss gender inclusive language in order to make potential non-binary and transgender participants more comfortable with participating in our research, which expands our outreach and sample diversity (without changing our eligibility criteria). Our team will continue to make every effort possible to make the screening, consent, scheduling and visit processes as seamless and efficient as possible to minimize participant hesitancy due to study time commitment.

With the approval of the IRB reliance agreement with Beth Israel Deaconess Medical Center (BIDMC) in June 2023, we added BIDMC as an additional recruitment site. Study staff at BIDMC started recruiting in-person at BIDMC Gynecology and send outreach letters to recruit patients retroactively.

We also added Dr. Raymond Anchan as a second referring provider to help with recruitment at the Brigham and Women's Hospital.

Actual or anticipated problems or delays and actions or plans to resolve them

During Year 4, we fell short of our projected quarterly enrollment goal despite approaching 82 potential participants, a 130% increase in the total annual approaches compared to Year 3. As discussed above, we took actions to address low enrollment. We expanded our recruitment approach to prescreen patients of referring providers and inform the providers with potentially eligible patients on a daily basis to facilitate an efficient referral process and encourage continuous referral. We post multimedia material on the BCH CYWH social media page, send PI outreach letters to providers of the current and previous participants, added BIDMC as an additional recruitment site, and are working with the newly appointed Research Coordinator in the Division of Adolescent/Young Adult Medicine at BCH.

Changes that had a significant impact on expenditures

Because of delayed study visit volume and associated costs (such as lab assays), expenses associated with in-person visits were decreased. These expenses will be shifted to the upcoming quarters as we catch up to our enrollment goal. Overall, long term expenditures are anticipated to be unchanged.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

None to report.

Significant changes in use or care of human subjects

None to report.

Significant changes in use or care of vertebrate animals

Not applicable.

Significant changes in use of biohazards and/or select agents

Not applicable.

6. PRODUCTS:

• **Publications, conference papers, and presentations**

None to report.

Journal publications.

None to report.

Books or other non-periodical, one-time publications.

None to report.

Other publications, conference papers and presentations.

None to report

- **Website(s) or other Internet site(s)**

Information about the study is posted on our Center's website:

<https://bostoncenterendometriosis.org/research/>

Our study is also listed on clinicaltrials.gov:

<https://clinicaltrials.gov/study/NCT03928288?locStr=Boston,%20MA,%20USA&country=United%20States&state=Massachusetts&city=Boston&distance=50&cond=endometriosis&rank=5>

- **Technologies or techniques**

None to report.

- **Inventions, patent applications, and/or licenses**

None to report.

- **Other Products**

None to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name: Amy DiVasta, MD, MMSc

Project Role: Principal Investigator at Boston Children's Hospital

Research Identifier:

Nearest person month worked: 3.6

Contribution to Project: Dr. DiVasta continues to approve all materials and forms associated with the trial. She has been present at all ETU study visits, conducted subject physical exams, and reviewed all clinical relevant laboratory results and adverse events. She prepared the blinded DSMB reports. She has assured regular communication with all study co-investigators and collaborators, as well as the clinical trial staff, and has led regular team meetings. She has handled all correspondence with the FDA, and reviewed all interactions and communications with the IRB, including protocol amendments and the annual continuing review.

Name: Mark Hornstein, MD

Project Role: Principal Investigator at Brigham and Women's Hospital

Research Identifier:

Nearest person month worked: No change

Contribution to Project: Dr. Hornstein is responsible for the organization of recruitment procedures in the Center for Infertility and Reproductive Services at Brigham and Women's Hospital.

Name: Raymond Anchan, MD

Project Role: Principal Investigator at Brigham and Women's Hospital

Research Identifier:

Nearest person month worked: No change

Contribution to Project: Dr. Anchan is involved with recruitment procedures in the Center for Infertility and Reproductive Services at Brigham and Women's Hospital.

Name: Marc Laufer, MD

Project Role: Co-Investigator at Boston Children's Hospital and Brigham and Women's Hospital

Research Identifier:

Nearest person month worked: No change

Contribution to Project: Dr. Laufer continues to assist with the identification and recruitment of eligible subjects in the Gynecology Clinic at Boston Children's Hospital and the Center for Infertility and Reproductive Services at Brigham and Women's Hospital.

Name: Christine Sieberg, PhD

Project Role: Co-Investigator

Research Identifier:

Nearest person month worked: No change

Contribution to Project: Dr. Sieberg trained the Research Assistants in the administering of the Quantitative Sensory Testing (QST) and will provide expertise in the interpretation and administration of the pain measures used in the clinical trial, which she helped to create in order to capture the full experience of adolescent chronic pain. Dr. Sieberg is available to answer any questions or concerns regarding the QST testing interpretation or administration.

Name: Caterina Stamoulis, PhD

Project Role: Senior biostatistician

Research Identifier:

Nearest person month worked: No change

Contribution to Project: Dr. Stamoulis continues to assist in creating the reports for the DSMB meetings and oversees blinded and unblinded data for the study. She meets periodically with the study team to review the database.

Name: Esther Kim, BS

Project Role: Senior Research Assistant

Nearest person month worked: 5.3

Contribution to Project: Ms. Kim conducted study visits in the ETU, including delivering questionnaires, conducting QST and assisting with PWV testing. She is responsible for screening potential participants and managing recruitment webpages. She conducts the REDCap data double-checking procedure, manages study folders, performs data entry and enrolls patients. She has drafted amendments submitted to the IRB, assisted in preparing the annual report to the FDA, and prepared materials for the DSMB meetings as well as the monitor visits. She will be preparing for the next DSMB meeting and monitor visit in the upcoming quarter.

Name: Emma Draisin, BS

Dr. Laufer: No changes

Dr. Hornstein: No changes

Dr. Anchan was awarded a grant from the Children's Hospital Corporation dba Boston Children's Hospital that began in August 2022 below.

PI: Anchan 08/2022 – 07/2024 1.2
CHILDREN'S HOSPITAL CORPORATION DBA BOSTON CHILDREN'S HOSPITAL The
Reproductive Biology and Nociceptive Mechanisms of Endometriosis: A Stem
Cell Based Approach
To investigate genetic mechanisms of infertility in patients with and without endometriosis using
single cell RNA sequencing approaches in IVF patients.
No overlap.

Dr. Sieberg was awarded a grant from the National Institutes of Health that began in October 2022
as below.

PI: Shafrir 10/2022 – 09/2024 0.12
Project role: Co-Investigator
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN
DEVELOPMENT
The Role Of Neurotrophins In Chronic Pelvic Pain And Central Sensitization Among Adolescents
And Women With Endometriosis
The goals of this R21 are to investigate the relationship between β -NGF and BDNF measured in
peritoneal fluid and pain remediation following laparoscopic surgery for endometriosis and whether
this relationship is moderated by number of co-occurring pain conditions; to identify endometriosis
lesion characteristics that are associated with levels of β -NGF and BDNF and in peritoneal fluid;
and to evaluate the interaction between neurotrophic markers (β -NGF and BDNF) and the
inflammatory milieu in the peritoneal cavity to predict treatment response.
No overlap.

Dr. Stamoulis was awarded a grant from the National Science Foundation that began in September
2022 as below.

PI: Stamoulis 09/01/2022 – 08/31/2026 1.2 NATIONAL
SCIENCE FOUNDATION
CRCNS Research: Modeling Human Brain Development as a Dynamic Multi-Scale Network
Optimization Process
Using neuroimaging data collected over years of development from almost 12,000 adolescents,
advanced computational tools and engineering principles, the overarching goal of this project is to
understand how internal mechanisms in the brain control its functional circuits to optimally support
cognitive function. Research activities aim to quantify these mechanisms and their inherent
changes, as the brain becomes increasingly optimally connected with age, and to map these changes
onto fundamental aspects of cognitive processing. This research aims to transform mechanistic

understanding of the optimization of human brain circuits during the uniquely complex developmental period of adolescence.
No overlap.

What other organizations were involved as partners?

Organization Name: Brigham and Women's Hospital, Department of Obstetrics and Gynecology

Location of Organization: Boston, MA

Partner's contribution to the project: Brigham and Women's Hospital is another participating site in the current trial. Co-Investigators there (Drs. Anchan, Laufer, and Hornstein) are involved in the study protocol development and identification/recruitment of eligible study subjects. Co-Investigators participate in preparation for ongoing project meetings, and will ultimately participate in data analysis and manuscript preparation. Brigham and Women's Hospital research computing team provided support for the REDCap database.

Organization Name: Beth Israel Deaconess Medical Center (BIDMC), Department of Obstetrics and Gynecology

Location of Organization: Boston, MA

Partner's contribution to the project: Beth Israel Deaconess Medical Center is another participating site in the current trial. BIDMC research assistant, Meg Bolan, was trained and has been working on participant recruitment from BIDMC, and conduct of the study visits at BCH.

Organization Name: Boston Center for Endometriosis

Location of Organization: Boston, MA

Partner's contribution to the project: Urine and blood samples are stored utilizing facilities of the Boston Center for Endometriosis, located within Brigham and Women's Hospital.

8. SPECIAL REPORTING REQUIREMENTS

Not applicable.

9. APPENDICES:

Appendix: Written informed consent form, current version

This section only to be edited by IRB office.



Protocol Title: Novel, non-hormonal therapy for treatment of chronic pain due to endometriosis

Principal Investigator: Amy DiVasta, MD, MMSc

Use Plate or Print:

MRN#:

DOB:

Subject's Name:

Gender:

This consent form gives you important information about a research study. A research study helps scientists and doctors learn new information to improve medical practice and patient care.

Please read this consent form carefully and take your time making a decision. The first section gives you an overview of the key information you should know about the research study. More detailed information about these topics may be found in the pages that follow.

The form may contain words that you do not understand. Please ask questions about anything you do not understand. We encourage you to talk to others (for example, your friends, family, or other doctors) before you decide to participate in this research study.

Please check one of the following:

You are an adult participant in this study.

You are the parent or guardian granting permission for a child in this study.

If the participant is a child the use of "you" refers to "your child"

Summary of Important Information

We are asking you to participate in this research study. Participation in this research study is voluntary. You may choose not to take part in this research study or may choose to leave the research study at any time. Your decision will not impact the clinical care you receive at Boston Children's Hospital.

In this research study we want to learn more about a potential new therapy for pain associated with endometriosis. We want to determine if a non-hormonal medication, cabergoline, will help patients with endometriosis.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Cabergoline is a medication that is approved by the Food and Drug Administration (FDA) for treatment of other medical conditions. In this study, the use of cabergoline is investigational. This means the drug is not approved by the FDA for the treatment of endometriosis. Cabergoline is a “dopamine receptor agonist.” Cabergoline binds to and stimulates specific chemical receptors on our cells that respond to dopamine, a chemical your body uses to help cells communicate with each other. Studies of these types of drugs show that cabergoline may help to prevent endometriosis lesions from growing.

It is important to consider reasons why you would or would not want to participate in this research.

You do not have to be in this research study to be treated for endometriosis. Your healthcare provider has discussed with you what your clinical treatment options are and which clinical treatment(s) might be right for you considering your medical history. These clinical treatment options include continuing your current medical treatment, which may include oral contraceptive pills, norethindrone acetate, or an intrauterine device (IUD), without adding study medication. Each of the clinical treatment options has known rates of being effective, known risks, as well as possible drawbacks.

The study treatment has not yet been proven to be safe and/or effective for the treatment of endometriosis. The study treatment may work better, the same, or worse and may have less, more, and/or other risks compared to the clinical care options. It is important to consider the trade-offs of the clinical care options as well as this research study before you decide whether you take part or not take part in this research study.

If you decide to join this research study, the following things will happen: you will receive either the study drug (cabergoline) or a placebo pill (sugar pill) to take twice a week for 6 months. We will ask you to complete questionnaires, keep a symptom diary every day, have an ultrasound of the blood vessels, complete sensory testing, and provide urine and blood samples to give us information about how these treatments are working and about any potential side effects.

You will be “randomized” into one of two study groups. Randomization means that you are put into a group by chance. It is like flipping a coin. You have a 50% chance of being placed in either group. Neither you nor the research investigator can choose what group you will be in. Neither you nor the research investigator will know which drug you get until the study is over. But, if there is an emergency, the research investigator will be able to get this information.

The most important potential risks to know about are the potential side effects of cabergoline, which could include: upset stomach/nausea, constipation, dizziness, headache, tingling, or swelling of the hands or feet.



RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

The most important potential benefits to know about are: study drugs may help with your endometriosis pain, but they may not. You will receive the results of some research tests (cholesterol levels, liver function tests, hormonal status) to share with your primary care provider.

It will take you about *6 months* to complete this study. During this time, we will ask you to make 3 study visits.

The research funds will cover costs associated with the study. Study medications will be paid for by the study. You will receive up to \$225 for the completion of the study. Some of your travel related costs may be covered by the study, such as parking garage fees, up to \$10.

MRN: _____

Pt Name: _____

How are individuals selected for this research study?

You are being asked to participate in this research study because you have endometriosis and are experiencing pain. All participants are females between the ages of 15-40 years.

Patients who have cardiac valve disorders (including murmurs), high blood pressure, blood clots, active liver disease, breast cancer, fibrotic disorders, stroke or heart attack, or are taking other medications that affect dopamine (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are not eligible to participate. Patients who are currently breastfeeding, who have had a baby in the last 6 months, who are pregnant, or who plan to become pregnant in the next six months are not eligible to participate.

Why is this research study being conducted?

In this research study, we want to learn more about treatments for endometriosis that may help to control pain. We want to determine if a non-hormonal medication, cabergoline, will help patients with endometriosis in a different way than hormonal treatments help.

Cabergoline is a medication that is approved by the Food and Drug Administration (FDA) for treatment of an endocrine condition called hyperprolactinemia that also affects young women. In this study, the use of cabergoline is investigational. This means the drug is not approved by the FDA for the purpose we are studying, the treatment of endometriosis. Cabergoline is a "dopamine receptor agonist." Cabergoline binds to and stimulates specific chemical receptors on our cells that respond to dopamine, a chemical your body uses to help cells communicate with each other. Studies of these types of drugs show that cabergoline may help to prevent endometriosis lesions from growing.

Who is conducting this research study, and where is it being conducted?

The research study is being conducted at Boston Children's Hospital under the direction of Dr. Amy DiVasta, Co-Scientific Director for the Boston Center for Endometriosis, and physician in the Division of Adolescent Medicine. The study is also affiliated with Brigham and Women's Hospital under the direction of Dr. Mark Hornstein. Dr. Christine Sieberg and Dr. Marc Laufer are co-investigators.

A grant from the United States Department of Defense is providing funding for this study.

MRN: _____

Pt Name: _____

How many people will participate in this research study?

Approximately 80 people will participate in this six-month study at Boston Children's Hospital and Brigham and Women's Hospital.

What do I have to do if I am in this research study?

This is a six month study that involves 3 visits to the Experimental Therapeutics Unit (ETU) on the 6th floor of the main building at Boston Children's Hospital, plus 2 phone calls with the study team.

If you agree to participate in the study:

- Because no one knows if cabergoline is helpful for endometriosis, you will be "randomized" into one of the 2 study groups. *One group will receive drug and one group will receive placebo.* Randomization means that you are put into a group by chance. It is like flipping a coin. You will have a 1 in 2 chance of being placed in either group. Neither you nor the research investigator can choose what group you will be in.
- Since the expectations of patients and doctors can influence the results of a study, neither you nor the research investigator will know which drug you get until the study is over. But, if there is an emergency, the research investigator will be able to get this information.
- You will be asked to take one capsule by mouth twice per week for six months. These capsules will contain either the study drug or a placebo. The study drugs will be provided to you during your research visits in the ETU. You are responsible for remembering to take the capsules. We will give you a medication diary to help you remember to take your capsules. A study team member and a research nurse will teach you about these medications at your first visit.
- You should know that the placebo is a capsule that does not contain any medicine and we do not expect it will do anything for your health. We use a placebo so we do not know whether you are receiving the study drug.
- At each visit, your blood pressure and pulse will be taken twice, once lying down and once standing.
- You will be asked to provide a blood and urine sample at each visit. The total amount of blood taken at each visit will be no more than 40mL, or less than 3 tablespoons.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

-
- Before you start this research, you will be tested for pregnancy with a urine pregnancy test. You will be tested for pregnancy at each follow-up visit as well.
 - At the beginning of every visit, you will be asked to fill out questionnaires. These will ask questions about your symptoms/discomfort, mood, quality of life, and sexual satisfaction (if you have had sexual intercourse). These will take about 20 minutes to complete.
 - At the first visit, you will be asked to fill out a Health History questionnaire. This survey will contain questions about your date of diagnosis, stage of endometriosis, and medication history. This will take about 20 minutes to complete.
 - We will look in your medical record to see things like your past prescribed medications and date of past visits or surgeries.
 - At each visit, you will have a physical examination performed by a study physician to examine your skin, heart, and lungs.
 - At the first and last study visit, you will have a measurement of the thickness and stiffness of your blood vessels. The Pulse Wave Velocity (PWV) test uses a machine (called a SphygmoCor) to measure artery stiffness. You will lie quietly while study staff takes measurements from your neck to the top of your leg. Sticky patches, called electrodes, will be placed on your chest and an instrument that looks like a pen (an ultrasound probe) will measure the speed of your pulse. This test does not hurt and does not include any radiation exposure.
 - At each visit, you will complete testing of your skin sensations. This testing will be done with you seated comfortably in a recliner chair or bed. The testing procedure will ask you to report the touch, type of sensation, and pressure sensations applied to the abdominal (stomach) region. The test also includes your feelings of pressure and touch over the upper arm.
 - Threshold sensation: A plastic tip attached to a measurement probe will be brought into contact with your skin. The plastic tip will be brought into contact with the skin until a sensation of pain is felt. This will determine the pain threshold. This test will be repeated on the abdomen. As soon as the sensation of pain is felt, the test is over.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

- Wind-Up testing: The plastic tip will be applied to your arm every second for 10 seconds with the same pressure felt in the threshold sensation test. At the end of the 10 seconds trial, you will report your pain on a scale from 0-10. There will be a total of 3 trials with 10 seconds rest between each trial. This test will be repeated on the abdomen.

- Pressure sensation: A pressure algometer, a handheld instrument with a tip located on the end, will be applied to the nail of your middle finger. The pressure on the nail will be slowly increased until you experience discomfort. This test will be conducted 3 times. The test will be repeated on the abdomen.

- Between visits, we will ask you to keep a symptom diary to track whether you are having any pain, bleeding, and use of any medications for pain (such as ibuprofen). This symptom diary will be in the form of a paper diary which will be given to you at each visit.

- We will send your gynecology provider and/or your primary care doctor a letter informing him/her that you are participating in this study and may be receiving the study drug. We can also send them results from your laboratory studies that may help with your clinical care (like cholesterol levels). We will not release any information to your primary care doctor unless you sign a release form.

Study Visit Timeline	Visit 1: Baseline 2.5 to 3 hours	6 week phone call: 10 minutes	Visit 2: 3 Month 2 hours	18 week phone call: 10 minutes	Visit 3: 6 Month 2 to 2.5 hours
Consent	X				
Vital signs	X		X		X
Blood, urine, saliva samples	X		X		X
Health History	X				
Physical Examination	X		X		X

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Questionnaires	X	X	X	X	X
Medication Diary			X		X
Pulse Wave Velocity	X				X
Sensory Testing	X		X		X

What are the risks of this research study? What could go wrong?

Some procedures or treatments used in this research may present risks that are not well-known or understood. Therefore, there may be unforeseeable risks associated with participating in this research. Side effects of cabergoline could include: upset stomach/nausea, constipation, dizziness, headache, tingling, or swelling of the hands or feet. These side effects are likely to be short term and should go away when you stop taking the medication. We will be monitoring for any of these side effects carefully by using blood tests and questionnaires. If you have concerns, you should call your medical provider.

Possible Side Effects	Common Happens to >21 people out of every 100	Occasional Happens to 5-20 people out of every 100	Rare Happens to <5 people out of every 100
Cabergoline	<ul style="list-style-type: none"> • Nausea • Headache 	<ul style="list-style-type: none"> • Dizziness • Fatigue • Constipation • Weakness 	<ul style="list-style-type: none"> • Hot flashes • Heartburn • Dry mouth • Breast tenderness • Diarrhea • Swelling of hands or feet • Postural hypotension (low blood pressure) • Depression • Nervousness • Abnormal vision

Risks associated with a blood draw may include minor discomfort, bruising, fainting, and infection. When possible, we will draw blood at the time of a clinically-indicated procedure to reduce the number of needle sticks.

There is minor risk of pain during the skin testing; however, the sensations experienced should not feel worse

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

than shaving or bristles touching the skin. Experiences of the different sensory tests vary between participants. Some participants with low pain thresholds may be particularly sensitive to the touch of the tip and pressure algometer. You/Your child will be allowed to stop at any time.

Minor skin irritation is possible from the sticky patches placed on your skin for the vascular tests. You may be asked questions that make you uncomfortable or cause you to remember situations that were upsetting to you. You may become frustrated if you are asked questions that you do not know how to answer. You may not be able to answer all the questions and you do not need to answer any questions that you do not wish to answer. If you become upset at any time, you can stop the questionnaires. We will also offer to have you speak to someone about how you are feeling. It is possible that the study team could identify concerns for depression when you answer the questionnaires. If we became concerned for depressed mood, we would notify you and encourage you to allow us to share the information with your healthcare provider. Additionally, mental health resources would be made available to you.

If, during your participation in this research, there is reason to believe that you are at risk for being suicidal or otherwise harming yourself or others, the research team is required by law and Hospital policy to act on this suspicion. This may include notifying your therapist(s) if applicable, or other individuals. If you are under age 18 years and there is reason to believe that you are at risk of being suicidal or otherwise harming yourself or others, we are required to notify your parent(s)/guardian(s) and would not be able to assure confidentiality. We would let you know that we plan to disclose this information because we felt it best for your safety or the safety of others.

The effects of the research drug on the reproductive system (eggs) or to the developing fetus are unknown. For this reason, participants taking the drug should not become pregnant. To be a part of the research, you must remain on your hormonal medications (birth control pills, progestin-only pills, IUD) for pregnancy prevention. Before you start this research, you will be tested for pregnancy. You will be tested for pregnancy at each follow-up visit as well. During the research, if you become pregnant, there is a chance that you are pregnant, or you intend to become pregnant, you should contact the research investigator immediately so that we may provide medical assistance and counseling. If you become pregnant during the research, we must withdraw you from the research.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Adolescent Assent for Pregnancy Testing:

Because participation in this research study could result in harm to a fetus, you cannot be pregnant while you are in the study. To be a part of the research, you must not have sex or you must use a barrier method of contraception, like condoms with spermicide every time. Before you start this research, you will be tested for pregnancy. One of the research nurses or doctors will meet privately with you to tell you your pregnancy test results. We will not tell your parent(s)/guardian(s) your results without your permission, except under certain circumstances (for example, if your life was at risk, or if the pregnancy was the result of suspected abuse). In these instances we may need to tell your parent(s)/guardian(s) or relevant authorities.

Even if we do not tell your parent(s)/guardian(s) about the positive results, they may guess that you are pregnant because we may need to tell them you cannot participate in the research. During the research, if you become pregnant, or if there is a chance that you are pregnant, you or your parent(s)/guardian(s) should contact the research personnel immediately so that we may provide assistance and counseling. If you become pregnant during the research, we must remove you from the research. Confidential pregnancy testing is available in the Boston Children's Hospital Adolescent/Young Adult Medicine Clinic who can be reached at 617-355-7181.

You have been informed about special concerns about pregnancy and unknown reproductive risks of the drug(s). You have informed the study personnel that you will abstain from sexual intercourse or use condoms with spermicide during the study.

Sign here (15-17 year olds): _____ Date: _____

What are the benefits of this research?

The study drugs may reduce your endometriosis pain and improve your quality of life, but they may not. The study medications will be provided at no cost. You will receive the results of some research tests (cholesterol levels, liver function tests, hormonal status) to share with your primary care provider. When we finish the research, we hope that we will know more about endometriosis and determine if this new therapy is effective. This may help other women with endometriosis in the future.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Will I receive my study results?

During this research we may learn information from the study results which could be important for your health or your treatment. This information will be made available to you and your health care provider. The information we may share is cholesterol levels, liver function tests, hormonal status; the results will be provided in letters mailed to your primary care provider.

Will my samples/information be used for research in the future?

Identifiable samples and/or identifiable private information collected from you during this study may be used for future research studies or shared with other researchers for future research. The identifiable samples and/or identifiable private information may be used for future research of endometriosis. If the research investigator distributes your samples and/or information to other researchers or institutions, your samples and/or information will be labeled with a research code without identifiers so that you cannot be identified. No additional consent will be requested for the future use of your samples or information.

If you have questions about storing samples or would like to request that samples be removed from storage, please let us know. It is not always possible to remove samples from storage or to retrieve samples from which identifiers have been removed and/or that have already been sent to other investigators.

Are there costs associated with this research? Will I receive any payments?

There are no costs associated with the study. We will pay for the study drugs and your visits in ETU. We will also give you a parking voucher or up to \$10 for each study visit for travel expenses.

You will receive a \$75.00 Target or Amazon gift card for each research visit that you complete (\$225.00 for the whole study). Gift cards are given out at your last study visit. If you leave the research study early, or if we have to take you out of the research study, you will be paid for the visits you have completed.

Although research funds will pay for some research-related items and services, we may bill your health insurer for routine items and services you would have received even if you did not take part in this research. You will be responsible for payment of any deductibles and co-payments required by your insurer for this routine care or other billed care. If you have any questions about costs to you that may result from taking part in the research, please speak with the research staff.

We will offer you the care needed to treat any injury that directly results from taking part in this research. We reserve the right to bill your insurance company or other third parties, if appropriate, for the care you get for

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

the injury. We will try to have these costs paid for, but you may be responsible for some of them. For example, if the care is billed to your insurer, you will be responsible for payment of any deductibles and co-payments required by your insurer.

Injuries sometimes happen in research even when no one is at fault. There are no plans to pay you or give you other compensation for an injury, should one occur. However, you are not giving up any of your legal rights by signing this form. If you think you have been injured or have experienced a medical problem as a result of taking part in this research, tell the person in charge of the research as soon as possible. The researcher's name and phone number are listed in this consent form. If you go to the Emergency Room or to another hospital or doctor it is important that you tell them that you are in this research study. If possible, you should give them a copy of this consent form.

If I do not want to take part in this research, what are the other choices?

Participation in this research study is completely voluntary. You do not have to participate. If you choose not to participate, you will still receive standard clinical care at Boston Children's Hospital or the Brigham and Women's Hospital. The medication cabergoline is not currently approved for this use and is only available as part of this study.

Are there other things I should know about?

If you choose to participate in this study, you will be assigned a unique study ID number. This is a random set of numbers and/or letters that does not contain any identifying information (birth date, medical record number, social security number). This number will be used to label all of your study questionnaires and samples. This helps to protect your confidentiality. All of your data will be stored in a locked filing cabinet in the research office. All computer files will be password protected. Your data will only be available to certain members of the study team who have been trained in conducting responsible and ethical research.

If we find out about new information from this research or other research that may affect your health, safety or willingness to stay in this research, we will let you know as soon as possible. For example, if we detect a previously unknown heart murmur, we will tell you as soon as possible and may ask your permission to share results with your medical provider.

Potential changes due to COVID-19 pandemic:

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

It is possible that the COVID-19 pandemic may disrupt usual research operations. If this disruption occurs, we may need to adapt the research activities to ensure the safety of you as the participant. These changes may include converting the in-person study visits to virtual (telehealth) visits. If it is determined that your visit must be converted to a virtual visit, we will notify you via secure email. Virtual visits will be conducted as a password-protected Zoom meeting. The changes that occur in a virtual visit are:

- We will not perform a physical exam, measure vital signs, conduct sensory testing, or conduct Pulse Wave Velocity testing. Please note: we will continue to monitor your safety and wellbeing through patient report at all phone calls and virtual visits.
- Zoom study visits will be shorter than in-person visits. They will last roughly 30-45 minutes.
- Study medication will be sent directly to your home via FedEx. You will return extra medication to the Hospital via USPS in a prepaid envelope.
- We will mail you a pregnancy test and ask that you perform it at home.
- We may ask you to have laboratory studies (blood test) obtained at a clinic, laboratory, or hospital close to your home in order to monitor for safety. We would provide you with the laboratory order form, and pay for all laboratory studies.
- Study questionnaires and the Daily Symptom Diary will be mailed to your home via USPS. You will return these to the study team via USPS in a prepaid envelope.

If necessary, visits may be done remotely until the restrictions are lifted. The visit schedule will not change. A study Research Assistant will contact you via secure email with a Zoom virtual visit link and password.

To protect your privacy, do not share the Zoom link (including the password) with anyone, make certain you are in a private space (for example, be in a room with no one else if possible), login from a secure Wi-Fi network (e.g. password protected), and turn your camera on.

If you have any further questions about virtual visits, medication delivery or other study logistics related to COVID-19, please contact the Research Assistants at **617-355-2212** or bce@childrens.harvard.edu.

Why would I be taken off the study early?

The research investigator may take you out of this study at any time. This would happen if:

- The research is stopped.
- You are not able to attend the research visits required.
- You become pregnant.
- You develop an adverse effect of a study medication.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

-
- You fail to follow the research requirements.
 - You need a treatment or medication that may not be taken while on the research or the research investigator feels it is in your best interest to be taken out of this research.

If this happens, the research investigator will tell you.

Other information that may help you:

Boston Children's Hospital is interested in hearing your comments, answering your questions, and responding to any concerns regarding clinical research. If you have questions or concerns, you may email IRB@childrens.harvard.edu or call (617) 355-7052 between 8:30 and 5:00, Monday through Friday.

Who may see, use or share your health information?

A copy of this consent form will be placed in your medical record. If you do not have a medical record at Boston Children's Hospital, one will be created for you.

Information collected during this research will become part of your medical record, if the information is related to the care you receive at Boston Children's Hospital. Medical records are considered permanent records; therefore, information cannot be deleted from the record. Medical records are available to health care professionals at Boston Children's Hospital and may be reviewed by Hospital staff when carrying out their responsibilities; however, they are required to maintain confidentiality in accordance with applicable laws and Hospital policies. Information contained in your medical record may not be given to anyone unaffiliated with Boston Children's Hospital in a way that could identify you without written consent, except as required or permitted by law.

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, under National Clinical Trial number NCT03928288, as required by U.S. law. This web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this web site at any time. The study sponsor (the Dept. of Defense) or the FDA may also see your health information.

Contact for Future Studies: Your participation in any research is completely voluntary and you should feel no pressure to participate if you are contacted about another research study. **Please check and initial one** of the options below regarding future contact about other research done by us or other researchers we are working with (collaborators).

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

_____ Yes, I may be contacted about participating in other research projects studying endometriosis or related conditions. I give permission for my contact information (name and mailing address and/or phone number) to be given to other researchers working with the study investigator at Boston Children's Hospital.

_____ No, I do not want to be contacted about other research projects. **Do not** give my contact information to the staff of any other research studies.

What should you know about HIPAA and confidentiality?

Your health information is protected by a law called the Health Information Portability and Accountability act (HIPAA). In general, anyone who is involved in this research, including those funding and regulating the study, may see the data, including information about you. For example, the following people might see information about you:

- Research staff at Boston Children's Hospital involved in this study;
- Medical staff at Boston Children's Hospital directly involved in your care that is related to the research or arises from it;
- Other researchers and centers that are a part of this study, including people who oversee research at that hospital;
- People at Boston Children's Hospital who oversee, advise, and evaluate research and care. This includes the ethics board and quality improvement program;
- People from agencies and organizations that provide accreditation and oversight of research;
- People that oversee the study information, such as data safety monitoring boards, clinical research organizations, data coordinating centers, and others;
- Sponsors or others who fund the research, including the government or private sponsors.
- Companies that manufacture drugs or devices used in this research;
- Federal and state agencies that oversee or review research information, such as the Food and Drug Administration, the Department of Health and Human Services, the National Institutes of Health, and public health and safety authorities;
- People or groups that are hired to provide services related to this research or research at Boston Children's Hospital, including services providers, such as laboratories and others;
- And/or your health insurer, for portions of the research and related care that are considered billable.

If some law or court requires us to share the information, we would have to follow that law or final ruling.

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Some people or groups who get your health information might not have to follow the same privacy rules. Once your information is shared outside of Boston Children's Hospital, we cannot promise that it will remain private. If you decide to share private information with anyone not involved in the study, the federal law designed to protect privacy may no longer apply to this information. Other laws may or may not protect sharing of private health information. If you have a question about this, you may contact the Boston Children's Hospital Privacy Officer at (857) 218-4680, which is set up to help you understand privacy and confidentiality.

Because research is ongoing, we cannot give you an exact time when we will destroy this information. Researchers continue to use data for many years, so it is not possible to know when they will be done.

We will also create a code for the research information we collect about you so identifying information will not remain with the data and will be kept separately. The results of this research may be published in a medical book or journal or be used for teaching purposes. However, your name or identifying information will not be used without your specific permission.

Your privacy rights

If you want to participate in this research study, you must sign this form. If you do not sign this form, it will not affect your care at Boston Children's Hospital now or in the future and there will be no penalty or loss of benefits. You can withdraw from the study and end your permission for Boston Children's Hospital to use or share the protected information that was collected as part of the research; however you cannot get back information that was already shared with others. Once you remove your permission, no more private health information will be collected. If you wish to withdraw your health information, please contact the research team.

You may have the right to find out if information collected for this study was shared with others for research, treatment or payment. You may not be allowed to review the information, including information recorded in your medical record, until after the study is completed. When the study is over, you will have the right to access the information again. To request the information, please contact the Hospital's Privacy Officer at (857) 218-4680.




Contact Information

I understand that I may use the following contact information to reach the appropriate person/office to address any questions or concerns I may have about this study. I know:

RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

 I can call...	 At	 If I have questions or concerns about
Investigator: Dr. Amy DiVasta	Phone: 617-355-7181 Pager: 617-355-7243 [0630]	<ul style="list-style-type: none"> ▪ General questions about the research ▪ Research-related injuries or emergencies ▪ Any research-related concerns or complaints
Research Contact Esther Kim Emma Draisin Meg Bolan	Phone: 617-355-2212 Pager: 1108 Email: bce@childrens.harvard.edu Phone: 617-677-0834	<ul style="list-style-type: none"> ▪ General questions about the study ▪ Research-related injuries or emergencies ▪ Any research-related concerns or complaints
Institutional Review Board	Phone: 617-355-7052	<ul style="list-style-type: none"> ▪ Rights of a research participant ▪ Use of protected health information. ▪ Compensation in event of research-related injury ▪ Any research-related concerns or complaints. ▪ If investigator/research contact cannot be reached. ▪ If I want to speak with someone other than the Investigator, Research Contact or research staff.

Documentation of Informed Consent and Authorization

- I have read this consent form and was given enough time to consider the decision to participate in this research.
- This research has been satisfactorily explained to me, including possible risks and benefits.
- All my questions were satisfactorily answered.
- I understand that participation in this research is voluntary and that I can withdraw at any time.
- I am signing this consent form prior to participation in any research activities.
- I give permission for participation in this research and for the use of associated protected health information as described above (HIPAA).



RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Parent/Legal Guardian Permission (if applicable)

If the child to be involved in this research is a foster child or a ward of the state please notify the researcher or their staff who is obtaining your consent.

■ _____
 Date (MM/DD/YEAR) Signature of **Parent or Legal Guardian** Relationship to child

Child Assent

■ _____
 Date (MM/DD/YEAR) Signature of **Child/Adolescent Participant**

Adult Participant (if applicable)

■ _____
 Date (MM/DD/YEAR) Signature of **Adult Participant**



RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____

Research Investigator /or Associate's Statement & Signature

- I have fully explained the research described above, including the possible risks and benefits, to all involved parties (participant /parents/legal guardian as applicable).
- I have answered and will answer all questions to the best of my ability.
- I will inform all involved parties of any changes (if applicable) to the research procedures or the risks and benefits during or after the course of the research.
- I have provided a copy of the consent form signed by the participant / parent / guardian and a copy of the hospital's privacy notification (if requested).

■ _____
 Date (MM/DD/YEAR) Signature of **Research Investigator or Associate**

Witness Statement & Signature

A witness must be present for the entire consent process in the following situations (please check the appropriate box)

- The individual cannot read and this consent document was read to the participant or legal representative,
or
 The individual has certain communication impairments that limit the participant's ability to clearly express consent or
 Situations where the IRB requests a witness be present: please specify _____

I confirm that the information in this consent form was accurately explained to the participant, parent or legally authorized representative, the individual appeared to understand the information and had the opportunity to ask questions, and that informed consent was given freely.

☐ _____
 Date (MM/DD/YEAR) Signature of Witness



RESEARCH CONSENT FORM

MRN: _____

Pt Name: _____
